News Report | April 16, 2020
Pear Receives FDA Clearance For ‘Somryst’ Insomnia Digital Therapeutic
On March 26, 2020, Pear Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted authorization for the Somryst™ prescription digital therapeutic (PDT) for chronic insomnia. Somryst is intended for use in the treatment of those 22 years of age and older.
The PDT is an app that consists of a nine-week program that includes cognitive behavioral therapy and restricting sleep to a limited window of time. Somryst can be used on a mobile device, such as a smartphone or tablet. Somryst is available by prescription only by a licensed health care professional.
The FDA submission was . . .